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Identity 
Other names: G-ALPHA-q; GAQ 
HGNC (Hugo): GNAQ 
Location: 9q21.2 
Local order: Between GNA14, CEP78. 
DNA/RNA 
Description 
The GNAQ gene is composed of 7 exons spanning a 
region of 310993 nucleotides. 
Transcription 
Transcript length is 6539 bp. Length of ORF is 1080 
bp. 
Pseudogene 
GNAQP in 2q14.3-q21. 
Protein 
Description 
Amino acid residues: 359. Molecular weight: 42141 
daltons. 
GNAQ is a proto oncogene which encodes for alpha 
subunit of 'q' class of heterotrimeric GTP binding 
protein. 
Expression 
GNAQ is ubiquitously expressed in all tissues. 
Localisation 
Cytoplasm. Signaling occurs at the membrane. 
 
Diagram of GNAQ gene. The transcribed exons are represented in purple, the 5' and 3' untranslated region is represented in yellow. 
The exon numbers are indicated on the top and the number of base pairs per exon is indicated at the bottom. Introns are represented by 
black bars along with the number of base pairs. The arrows represent the start and stop codons. 
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Schematic diagram of functional domains of GNAQ protein. The blue boxes represent the exons with exon numbers and the amino 
acid numbers on the top. The inner boxes represent the different domains: Helical domain (Green), Switch regions (Orange) (SR1: 182-
192, SR2: 204-224, SR3: 236-247) are involved in conformational change based on the binding of GDP or GTP, GTPase domain (Pink) 
is essential for hydrolysis of GTP to GDP. N and C represent the amino and carboxy terminals of the protein respectively. The two arrows 
(R183, Q209) represent the hotspot mutations. Adapted from Mizuno and Itoh, 2009. 
 
Function 
GNAQ mediates signal between the G protein coupled 
receptor (GPCR) and downstream effectors. Receptor 
activation by ligand binding causes the activation of 
GNAQ by catalyzing the release of GDP and binding 
of GTP. In its active form GTP-bound GNAQ causes 
the release of the beta and gamma subunits of the 
heterotrimeric G-protein. GTP-GNAQ and beta and 
gamma subunits transfer the receptor-mediated signal 
to downstream effectors through secondary messengers 
which participate in diverse signaling pathways to 
evoke different effectors. The known effectors for 
GNAQ include PLC beta, p63-RhoGEF, Trio, and Duet 
(Maize et al., 2005; Eom et al., 2009). GNAQ has been 
shown to activate the MAP kinase pathway, possibly 
via DAG-mediated activation of protein kinase C 
isoforms. GNAQ has an intrinsic GTPase domain at the 
C terminus which causes the hydrolysis of GTP to GDP 
and the G-alpha-GDP re-associates with G-beta and G-
gamma subunits. 
Homology 
GNAQ is one of the four members belonging to the 
Gq-alpha family. Compared to GNAQ the other three 
members G11alpha, G14alpha, G16 alpha have 90%, 
80%, and 57% amino acid sequence homology, 
respectively (Eom et al., 2009). 
Mutations 
Note 
Somatic mutations of GNAQ affect codons 183 and 
209 resulting in R183Q, Q209L, Q209P, Q209R, and 
Q209Y. 
Germinal 
No germinal mutations have been described. 
Somatic 
Somatic mutations in GNAQ have been described in 
melanocytic neoplasia (Hubbard et al., 2006; Onken et 
al., 2008; Küsters-Vandevelde et al., 2009). In Uveal 
Melanoma, 97% of the hotspot mutations cause the 
amino acid substitution Q209L, the other 3% of 
mutations cause amino acid change to R183Q. The 
Glutamine 209 of GNAQ is similar to residue 61 of 
RAS protein. The Q209 and R183 mutations cause 
complete or partial loss of intrinsic GTPase activity 
respectively thereby locking the protein in a 
constitutively active form. Q209 and R183 mutations 
occur in a mutually exclusive pattern in human 
neoplasia. Mutations in GNAQ are also mutually 
exclusive from the hotspot mutations in GNA11, which 
belongs to the same family and shares 90% sequence 
homology. GNAQ mutations are not concomitant with 
other common oncogenic mutations in BRAF, NRAS 
or KIT found in melanocytic neoplasia. 
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Schematic representation of GNAQ mutations in melanocytic neoplasms. The purple boxes represent the exons with the exon 
numbers indicated within the boxes, amino acid numbers indicated on top. The arrows represent the two hotspot mutations along with the 
amino acid change. N and C represent the amino and carboxy terminal of GNAQ protein. 
 
Categories Subtypes GNA11 Ex5 GNAQ Ex5 Neither Total 









%   
Blue nevi 
Amelanotic blue nevus 0 0.0% 7 70.0% 3 30.0% 10 
Cellular blue nevus 3 8.3% 26 72.2% 7 19.4% 36 
Common blue nevus 4 6.7% 39 65.0% 17 28.3% 60 
Nevus of Ito 0 0.0% 0 0.0% 7 100.0% 7 
Nevus of Ota 1 5.0% 2 10.0% 17 85.0% 20 
Malignant blue nevus 1 16.7% 2 33.3% 3 50.0% 6 




Conjunctival melanoma 0 0.0% 0 0.0% 9 100.0% 9 
Uveal melanoma, 
primary 
52 31.9% 73 44.8% 38 23.3% 163 
Uveal melanoma, 
metastasis 
13 56.5% 5 21.7% 5 21.7% 23 
Uveal nevus 0 0.0% 1 100.0% 0 0.0% 1 
Total 65 33.2% 79 40.3% 52 26.5% 196 
Other nevi 
Common nevus 0 0.0% 0 0.0% 22 100.0% 22 
Congenital nevus 0 0.0% 0 0.0% 17 100.0% 17 
Deep penetrating nevus 0 0.0% 0 0.0% 27 100.0% 27 
Spitz nevus 0 0.0% 0 0.0% 19 100.0% 19 
Atypical Spitz tumor 0 0.0% 0 0.0% 20 100.0% 20 




Acral 0 0.0% 0 0.0% 47 100.0% 47 
CSD 0 0.0% 1 1.4% 73 98.6% 74 
Mucosal 0 0.0% 0 0.0% 62 100.0% 62 
NonCSD 0 0.0% 0 0.0% 90 100.0% 90 
Total 0 0.0% 1 0.4% 272 99.6% 273 
Grand Total  
713 
 
Table representing the exon 5 mutation frequencies of GNAQ and GNA11 in melanocytic neoplams. 
 
 










The hotspot mutation of Q209 in Exon 5 is found in 
55% of blue nevi. The R183 mutation in Exon 4 is less 
common and is found in 1% of blue nevi. The 
mutations of GNAQ or its paralog GNA11 are expected 
to be early events in oncogenesis.  
 
A mutation in either gene alone is often found in 
benign proliferations of dermal melanocytes such as 
blue nevi. 
Prognosis 
Blue nevi are typically benign melanocytic nevi that 
rarely progress to melanoma (malignant blue nevus). 
Cytogenetics 
Blue nevi typically lack the presence of chromosomal 
aberrations. 
Categories Subtypes GNA11 Ex5 GNAQ Ex5 Neither Total 









%   
Blue nevi 
Amelanotic blue nevus 0 0.0% 7 70.0% 3 30.0% 10 
Cellular blue nevus 3 8.3% 26 72.2% 7 19.4% 36 
Common blue nevus 4 6.7% 39 65.0% 17 28.3% 60 
Nevus of Ito 0 0.0% 0 0.0% 7 100.0% 7 
Nevus of Ota 1 5.0% 2 10.0% 17 85.0% 20 
Malignant blue nevus 1 16.7% 2 33.3% 3 50.0% 6 
Total 9 6.5% 76 54.7% 54 38.8% 139 
 
Table representing the exon 5 mutation frequencies of GNAQ and GNA11 in blue nevi. 
 
 
Categories Subtypes GNA11 Ex5 GNAQ Ex5 Neither Total 

















0 0.0% 0 0.0% 9 100.0% 9 
Uveal melanoma, 
primary 
52 31.9% 73 44.8% 38 23.3% 163 
Uveal melanoma, 
metastasis 
13 56.5% 5 21.7% 5 21.7% 23 
Uveal nevus 0 0.0% 1 100.0% 0 0.0% 1 
Total 65 33.2% 79 40.3% 52 26.5% 196 
 




The hotspot mutation of Q209 in Exon 5 is found in 
45% of primary uveal melanoma and 22% of metastatic 
uveal melanomas. R183 mutation in Exon 4 is less 
common and is found in 3% of uveal melanoma. 
Prognosis 
Uveal melanoma is the most common primary 
intraocular malignancy with a 10 year survival rate of 
approximately 50%. Uveal melanoma has a high 
propensity of metastasis to the liver. The prognosis f 
uveal melanoma is highly dependent on the presence of 
additional genetic alterations, primarily loss of 
chromosome 3 and trisomy 8q. 
Cytogenetics 
Uveal melanoma has been shown to have frequent 
chromosomal aberrations like monosomy 3, trisomy 8q 
and recently 80% of uveal metastasis have been shown 
to have mutations in BAP1. 
Primary melanocytic neoplasms of the 
central nervous system 
Note 
Recently GNAQ Q209 mutations have also been shown  
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to be present in primary melanocytic neoplasms of the 
central nervous system, (in this study GNAQ exon 4 
was not investigated). Primary melanocytic neoplasms 
of the central nervous system (CNS) are rather rare
tumors, originating from melanocytes that are 
considered to be derived from the leptomeninges. The 
tumors represent a spectrum in terms of malignant 
potential. Some are classified as low-grade 
melanocytomas, others as intermediate malignancy and 
some as overtly malignant melanomas. 
Prognosis 
Highly varied, depending on the grade of the tumor. 
Other diseases 
Note 
So far no activating mutations of GNAQ in other 
cancers have been reported. Collectively four studies to 
date have sequenced more than 1500 tumor samples of 
a collection of various major tumor types and failed to 
identify any mutations in other settings than the ones 
described above.  
There have been two reports indicating that promoter 
associated expression of GNAQ may be of importance. 
One of the reports indicates the presence of a 
dinucleotide SNP in the promoter region as a genetic 
risk factor for cardiac hypertrophy. The second repo t 
links promoter associated expression differences to 
polycystic ovary syndrome, raising the possibility that 
expression levels could be relevant in some settings. 
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